Drug giant Merck (NYSE: MRK) is selling its Diosynth contract drug manufacturing facility in Research Triangle Park to FujiFilm Corporation.

The deal was announced Sunday night. Financial terms were not disclosed.

Merck operates a large vaccine manufacturing facility in Durham.

The Diosynth facility, which employs some 300m people, is part of Merck’s BioManufacturing Network. Merck is also selling its MSD Biologics facility in the United Kingdom as part of the deal.

“Fujifilm continues to build upon its ongoing commitment to delivering pharmaceutical business,” said Shigetaka Komori, president and chief executive officer of FujiFilm Corporation, in a statement. “This acquisition provides an important addition to our pharmaceutical business with diverse capabilities and technical expertise in production of protein therapeutics.”

Merck has agreed to “certain continued development and manufacturing activities” at the facilities as part of the deal.

“When Merck/ MSD combined its biopharmaceutical manufacturing services businesses in the United States and U.K. into the Merck BioManufacturing Network, we established one of the world’s leading biopharmaceutical contract manufacturing organizations,” said Willie Deese, president of Merck’s Manufacturing Division. “With this transaction, Merck/MSD becomes a key customer that will continue to benefit from the expertise and experience of the combined businesses in biologics development and manufacturing.”

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.